Summary
Health Canada has authorized Svemia, the first generic version of the weight loss drug Wegovy, which is expected to be 45% to 90% cheaper than the brand-name equivalent. This approval marks a major step forward for patient accessibility, with six additional generic semaglutide versions currently under review to further drive down costs.
A cheaper path to a weight loss drug that’s been out of reach for many Canadians may be on the way.
Health Canada authorized the first generic semaglutide injection for weight loss on June 29, 2026. The drug, called Svemia, is a generic version of Wegovy, the brand-name semaglutide injection widely used for chronic weight management, and was developed by Canadian pharmaceutical company Apotex.
What This Approval Actually Means
Generic drugs are required to be pharmaceutically equivalent to their brand-name counterparts. Health Canada’s review confirmed that Svemia meets the same standards for safety, efficacy, and quality required of all generic drugs sold in Canada, meaning it’s expected to work the same way as Wegovy, just at a different price point.
The drug is indicated for once-weekly use in patients aged 12 and over, as a supplement to a reduced-calorie diet and increased physical activity for chronic weight management, the same indication as the brand-name version.
This isn’t Canada’s first brush with generic semaglutide, either. On April 28, 2026, Canada became the first G7 country to approve a generic version of semaglutide at all; that approval was for the diabetes indication. A second generic, also for diabetes, followed on May 1. This latest approval marks the third generic semaglutide product authorized in Canada overall, and the first specifically for weight loss.
Why It Matters: Cost
The headline reason this matters to most Canadians is cost. Generic medications in Canada are typically 45 to 90% cheaper than their brand-name equivalents, according to Health Canada. For a drug class that has drawn criticism for being expensive and often poorly covered by insurance, that price gap could make a meaningful difference for patients who’ve been priced out of treatment.
Health Canada also noted the approval is expected to ease pressure on the broader healthcare system, not just individual patients’ wallets, given how widely semaglutide-based treatments are now prescribed.
More Generics Are Coming
This won’t be the last word on generic semaglutide in Canada. Health Canada is currently reviewing six additional generic semaglutide submissions from other companies, with more regulatory decisions expected in the coming weeks and months. As more generics enter the market, competition is generally expected to drive prices down further.
Health Canada has also noted that its review timelines for generic drug submissions are shorter than many other international regulators, part of why Canada was able to beat other G7 countries to market with a generic version of this drug class.
What Happens Now
As with all approved drugs, Health Canada says it will continue to monitor the safety and effectiveness of generic semaglutide products once they’re on the market, and will act if any safety concerns arise.
For now, the approval is a significant step for Canadians who’ve watched the cost of semaglutide-based weight loss treatment remain a major barrier to access. If you’re currently taking or considering Wegovy for weight management, it’s worth asking your doctor or pharmacist when generic alternatives like Svemia are expected to become available, and what that could mean for your treatment costs going forward.
Subscribe to The Health Insider newsletter where you’ll find many more insights – delivered straight to your inbox.
~ Read more from The Health Insider ~
- Ottawa Indefinitely Extends the MAID Exclusion for Mental Illness. Here Is What Changes.
Ottawa has indefinitely extended the exclusion of mental illness as a sole condition for MAID. Learn what changes and what the data shows. - Magnesium vs. Melatonin for Sleep: What Science SaysCompare magnesium and melatonin for sleep. Discover Canadian stats, expert evidence, optimal dosages, risks, and which supplement fits you.
- Women’s Heart Attacks: The Fatal Gap in Care You Need To Know AboutWomen experience heart attacks differently than men and are often misdiagnosed. Know the subtle warning signs and how to insist on sex-specific testing.
- Ontario Pays Private Clinics More. Wait Times Keep Rising.A CCPA report shows Ontario’s for-profit health clinics cost taxpayers more, increase wait times, and lead to unlawful patient fees.
- A Canadian Guide to Hip and Knee Replacement Wait ListsUnderstand how Canada’s 26-week hip and knee replacement wait list benchmark works, which stage you are in, and how to advocate for your care.
- AI Is Helping Write Medical Records. Patients Still Need to Read Them.Ambient AI scribes are writing doctor notes, but an Ontario audit found errors across vendors. Learn why reviewing medical records matters.
The information provided on TheHealthInsider.ca is for educational purposes only and does not substitute for professional medical advice. TheHealthInsider.ca advises consulting a medical professional or healthcare provider when seeking medical advice, diagnoses, or treatment. To read about our editorial review process click here.
